Euro Diagnostica Immunoscan CCPlus® based on CCP2 – The ACPA of highest Diagnostic Value

September 12, 2013 - Company News, Product News, Disease Area News
The Immunoscan CCPlus® is a CCP2-test for diagnosis of patients with rheumatoid arthritis (RA), developed by Euro Diagnostica in collaboration with leading scientists. The test has for several years been considered the golden standard (ref 1); a position that is now further emphazised by a study presented during the 11th Dresden Symposium on Autoantibodies.

Recently some other RA biomarkers of the same protein family, ACPA (anti-citrullinated protein antibodies) have been introduced on the market. The diagnostic value of CCPlus® in comparison with two of them; CCP3.1 and MCV, was investigated in an in-house study. Our results were compared to data presented in peer reviewed publications and confirm the position of anti-CCP2 as the ACPA test of highest diagnostic value. 

The study was presented during the 11th Dresden Symposium on Autoantibodies, September 2, 2013. You find the link to the poster here.

A literature survey summarising the role of anti-CCP2 in RA diagnosis is provided here.


1. Pruijn et al. Arthritis Research & Therapy 2010, 12:203

« Back